Milestone Pharmaceuticals’ Cardamyst etripamil nasal spray is now available in US pharmacies, and a national sales campaign is expected to begin within the next few weeks, the company said. The FDA approved Cardamyst for the treatment of paroxysmal supraventricular tachycardia (PSVT) in December 2019. According to Milestone, a patient assistance program will provide financial assistance to patients, capping copays at $25.
Earlier this month, Milestone announced that the EMA has accepted the company’s MAA for etripamil nasal spray for the treatment of PVST. If approved, the nasal spray would be marketed as Tachymist in Europe.
In addition to the PVST indication, Milestone is also developing etripamil nasal spray for the treatment of atrial fibrillation with rapid ventricular rate (AFib-RVR). The company has said that it plans to submit an sNDA for the AFib-RVR indication if a planned Phase 3 trial is successful.
Milestone President and CEO Joseph Oliveto commented, “Many patients have been waiting for help to take greater control of their PSVT condition. Now that Cardamyst is available, patients have access to a convenient, self-administered option designed to treat episodes of PSVT wherever and whenever they occur. Beyond availability, our team continues to engage insurers with the goal of having Cardamyst widely covered and affordable.”
Read the Milestone Pharmaceuticals press release
